| UHC Commercial Medical & Drug | Off-Label/Unproven Specialty Drug Treatment – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Reblozyl® (Luspatercept-Aamt) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Skyrizi® (Risankizumab-Rzaa) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Surgery of the Wrist or Thumb – Commercial and Individual Exchange Medical Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Susvimo® (Ranibizumab Injection) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Complement Pathway Inhibitors – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| Wellcare Hawaii Medicaid Clinical | Aquatic Therapy | 2026-08-01 |
| Wellcare Hawaii Medicaid Clinical | Transportation for Care Coordination | 2026-08-01 |
| BCBS Illinois Medical Policies | FDA - Drugs, Biologicals, Cellular and Gene Therapies | 2026-08-01 |
| BCBS Illinois Medical Policies | Gene Therapy for Inherited Retinal Dystrophy | 2026-08-01 |